NCT03196310

Brief Summary

Single blinded PRP vs. Corticosteroid vs. Placebo (normal saline) intra-articular injection for basal joint arthritis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 21, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 22, 2017

Completed
1.2 years until next milestone

Study Start

First participant enrolled

September 1, 2018

Completed
6.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2025

Completed
Last Updated

April 8, 2026

Status Verified

April 1, 2026

Enrollment Period

6.6 years

First QC Date

June 21, 2017

Last Update Submit

April 2, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Disabilities arm shoulder and hand score

    functional score

    1 year

Secondary Outcomes (1)

  • Pinch Strength

    1 year

Other Outcomes (1)

  • Visual Analog Score

    1 year

Study Arms (3)

PRP

EXPERIMENTAL

Intra-articular injection of platelet rich plasma.

Drug: Platelet Concentrate

Corticosteroid

ACTIVE COMPARATOR

Intra-articular injection of kenalog.

Drug: Corticosteroid injection

Normal Saline

PLACEBO COMPARATOR

Intra-articular injection of normal saline

Other: Normal Saline

Interventions

Platelet Rich plasma

PRP

Kenalog

Corticosteroid

Control Group - Placebo

Normal Saline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stage 1-3 osteoarthritis of the basal joint

You may not qualify if:

  • Patients with Stage 4 1st carpometacarpal joint arthritis as described by Eaton
  • Patients who have received a corticosteroid injection in the last year to the 1st CMC joint on the proposed study side
  • Patients who have scaphotriquetral, radioscaphoid, or scaphotrapezial osteoarthritis
  • Patients who have concurrent DeQuervain's tenosynovitis or intersection syndrome or have been treated for either of these in the last 3 months
  • Patients undergoing evaluation of cervical radiculopathy
  • Patients with fibromyalgia or inflammatory rheumatic disease
  • Patients with Pressier disease, Kienbock's, or avascular necrosis of the scaphoid
  • Patients with any history of primary or secondary bone tumor
  • Patients that are pregnant or terminally ill

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Orthopedic Associates of Southwest Ohio

Centerville, Ohio, 45459, United States

Location

MeSH Terms

Interventions

Adrenal Cortex HormonesSaline Solution

Intervention Hierarchy (Ancestors)

HormonesHormones, Hormone Substitutes, and Hormone AntagonistsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Patients will be blinded to therapy they receive
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 21, 2017

First Posted

June 22, 2017

Study Start

September 1, 2018

Primary Completion

March 31, 2025

Study Completion

March 31, 2025

Last Updated

April 8, 2026

Record last verified: 2026-04

Locations